Bioptik Technology (ROCO:4161) NonCurrent Deferred Liabilities: NT$0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4161 Bioptik Technology Inc ROCO:4161
69 GF Score
Price NT$22.40
GF Value NT$28.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bioptik Technology NonCurrent Deferred Liabilities?

Bioptik Technology ROCO:4161 +1.82% 69 NonCurrent Deferred Liabilities is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:4161 with a GF Score™ of 69/100 and a GF Value™ of NT$28.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Bioptik Technology's non-current deferred liabilities for the quarter that ended in Mar. 2026 was NT$0.0 Mil.

Bioptik Technology NonCurrent Deferred Liabilities Related Terms

Bioptik Technology NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Bioptik Technology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioptik Technology NonCurrent Deferred Liabilities Chart

Bioptik Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioptik Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4161
69GF Score
Bioptik Technology Inc ROCO:4161
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of NT$0.0 Mil mean?
Bioptik Technology (ROCO:4161) has a NonCurrent Deferred Liabilities of NT$0.0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Bioptik Technology and its competitors.
Is Bioptik Technology's NonCurrent Deferred Liabilities too high?
Bioptik Technology's current NonCurrent Deferred Liabilities is NT$0.0 Mil. Overall, Bioptik Technology has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's NonCurrent Deferred Liabilities compare to ABT and SYK?
Bioptik Technology's NonCurrent Deferred Liabilities of NT$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Bioptik Technology and its competitors. Bioptik Technology's current NonCurrent Deferred Liabilities is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.93, compared to a current price of NT$22.40 — trading 22.6% below its estimated fair value. The current NonCurrent Deferred Liabilities is NT$0.0 Mil. Bioptik Technology's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current NonCurrent Deferred Liabilities is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioptik Technology (ROCO:4161) Overvalued in 2026?

Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued. The current stock price of NT$22.40 is trading 22.6% below its estimated GF Value™ of NT$28.93. GuruFocus considers Bioptik Technology to be Modestly Undervalued.

Key valuation signals for ROCO:4161:

  • NonCurrent Deferred Liabilities: NT$0.0 Mil
  • GF Value™: NT$28.93 vs. price of NT$22.40 (22.6% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioptik Technology Business Description

Address No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
69GF Score

Get the complete analysis for ROCO:4161

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.40
Price
NT$28.93
GF Value